Quick Takeaways
- Erik Harris has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $3,021,369.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Erik Harris
- Location
- Redwood City, CA
- Summary
- The estimated net worth of Erik Harris is at least $3,021,369 dollars as of 20 Apr 2026. Erik Harris is the EVP & Chief Commercial Officer of Ultragenyx Pharmaceutical Inc. and owns shares of Ultragenyx Pharmaceutical Inc. (RARE) stock worth about $2.48M. Erik Harris is the Director of Denali Therapeutics Inc. and owns shares of Denali Therapeutics Inc. (DNLI) stock worth about $347.7K. Erik Harris is the Director of Rezolute, Inc. and owns shares of Rezolute, Inc. (RZLT) stock worth about $193K.
- Signature
- /s/ Karah Parschauer, attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Erik Harris and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Ultragenyx Pharmaceutical Inc. ($2,480,689).
- Past-year value change for that position: -$240,289.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Erik Harris
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc. | EVP & Chief Commercial Officer | $2,480,689 | -$240,289 | -8.8% | 16 Apr 2026 |
| DNLI | Denali Therapeutics Inc. | Director | $347,690 | 31 May 2024 | ||
| RZLT | Rezolute, Inc. | Director | $192,990 | 19 Nov 2025 | ||
| INZY | Inozyme Pharma, Inc. | Director | 03 Oct 2024 |
Insider Transactions Reported by Erik Harris:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.